Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 39 Neoplasm Metastasis 6 Neoplasms 3 Neoplasms by Site 2 Melanoma 2 Hereditary Sensory and Autonomic Neuropathies 2 Glioblastoma 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Diseases 2 Anatomic Stage II Breast Cancer AJCC v8 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Sarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neuroblastoma 1 Meningioma 1 Lung Neoplasms 1 Locoregional Recurrence 1 Locally Advanced (Inoperable) or Metastatic Breast Cancer 1 Liposarcoma 1 Leiomyosarcoma 1 Head and Neck Neoplasms 1 HR+/HER2- Breast Cancer 1 HER2 Negative Breast Cancer Not Immediately Operated 1

Interventions

ribociclib 1 Letrozole 1 Goserelin 1 Chemotherapy, Adjuvant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HER2 Negative Breast Cancer × ribociclib × 90 days × Clear all

NCT06953882 2026-05-26

SELECT

Yale University

Phase 2 Recruiting

HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡